Uniqure NV (QURE NASDAQ) stock market data APIs
$14.7067
1.82(12.4%)
as of September 15, 2025
Try our APIs with
free plan!
Uniqure NV Financial Data Overview
Price chart is built with
Anychart
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Prev. Close
14.7067
Open
16.5271
High
16.5556
Low
14.7292
52 wk Range
4.45-19.18
Market Cap
904 M
Shares Outstanding
54 867 K
Revenue
14 337 K
EPS
-0.69
Beta
0.134
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Uniqure NV (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Uniqure NV data using free add-ons & libraries
Get Uniqure NV Fundamental Data
Uniqure NV Fundamental data includes:
- Net Revenue: 14 337 K
- EBITDA: -146 439 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-29
- EPS/Forecast: -0.89
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Uniqure NV News
New
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement thera...
UniQure outlines planned BLA submission for AMT-130 in Q1 2026 amid regulatory alignment and pipeline momentum
Earnings Call Insights: uniQure N.V. (QURE) Q2 2025 MANAGEMENT VIEW * CEO Matthew Kapusta highlighted that "the first half of 2025 has been tremendously productive for the company as we advance AM...
uniQure shares tumble as Q2 revenue misses expectations
Investing.com - uniQure N.V. (NASDAQ:QURE) reported second quarter revenue that fell short of analyst expectations, though its loss per share was narrower than anticipated. The gene therapy company’...
uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares
UNIQURE NV (NASDAQ:QURE [https://www.chartmill.com/stock/quote/QURE]) REPORTS Q2 2025 EARNINGS: MIXED RESULTS AMID REGULATORY PROGRESS uniQure NV released its second-quarter 2025 financial results, r...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
